Clinical TrialApr 22, 2026, 08:02 AM
OPKO's ModeX Doses Patients in Phase 1 MDX2003 Lymphoma Study
AI Summary
ModeX Therapeutics, an OPKO Health company, has begun dosing patients in a Phase 1 study for MDX2003, a novel T-cell engager for relapsed or refractory B-cell lymphoma. This first-in-class tetraspecific antibody targets CD19 and CD20 on cancer cells and CD3/CD28 on T-cells, aiming to optimize tumor killing and address immune escape. The study will assess safety, tolerability, and immune activity, marking a significant milestone for the company's pipeline.
Key Highlights
- Patients dosed in Phase 1 study (MDX-2003-101) for MDX2003.
- MDX2003 targets relapsed or refractory B-cell lymphoma.
- Tetraspecific T-cell engager targets CD19, CD20, CD3, and CD28.
- B-cell lymphoma accounts for approximately 85% of lymphoma cases.
- Preclinical data presented at 2025 ASH and ESMO 2026.
Price Impact
More from OPK